Pramipexole News and Research

RSS

Boehringer Ingelheim Pharmaceuticals receives FDA approval for Mirapex ER in treatment of early PD

Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER® (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early idiopathic Parkinson's disease (PD). MIRAPEX ER is not indicated in advanced PD. Parkinson's disease is a chronic, slowly progressive and potentially debilitating neurological condition affecting nearly one million people in the U.S., with one person newly diagnosed every nine minutes.

22 Feb 2010

Reducing DA dosage causes acute withdrawal symptoms in Parkinson's patients

New research has shown that reducing the dosage of dopamine agonist (DA) drugs, a mainstay treatment for Parkinson's disease (PD), sometimes causes acute withdrawal symptoms similar to those reported by cocaine addicts -- including anxiety, panic attacks, depression, sweating, nausea, generalized pain, fatigue, dizziness and drug cravings. These symptoms can be severe, and are not alleviated by other PD medications.

12 Jan 2010

New systematic study for managing treatment-resistant bipolar depression

Depression in bipolar illness is often difficult to treat and life-threating. Frequently it fails to respond to standard treatments. In the current issue of Psychotherapy and Psychosomatics a new drug combination is suggested.

27 Oct 2009

Dopamine agonists trigger destructive behaviors

A new study conducted at Mayo Clinic reports that one in six patients receiving therapeutic doses of certain drugs for Parkinson's disease develops new-onset, potentially destructive behaviors, notably compulsive gambling or hypersexuality.

9 Apr 2009

Long-term effects of two common drugs for early Parkinson's similar

A study published online in the Archives of Neurology involving two common drugs used to treat early-stage Parkinson's disease shows that, while the drugs each have advantages and disadvantages, the overall impact tends to even out over a long period of treatment.

10 Mar 2009

New experimental treatment for Tourette's syndrome

The University of Rochester Medical Center (URMC) is leading a multi-center clinical research study of a new experimental treatment for Tourette's syndrome.The study will examine whether or not a drug that alters the chemical activity in the brain can alleviate the symptoms of the disease.

2 Dec 2008

Barr Labs to settle Mirapex and Aggrenox patent challenges

Barr Pharmaceuticals, Inc announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim's Mirapex product.

12 Aug 2008

Barr announces favorable ruling in Mirapex patent challenge

Barr Pharmaceuticals, Inc. has announced that U.S. District Court for Delaware has ruled in favor of its subsidiary, Barr Laboratories, Inc., in the challenge of the patent listed by Boehringer Ingelheim Pharmaceuticals, Inc. in connection with Boehringer Ingelheim's Mirapex(R) Tablets (pramipexole dihydrochloride) 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg.

26 Jun 2008

Barr receives approval for generic Mirapex tablets

Barr Pharmaceuticals, Inc. has announced that its subsidiary, Barr Laboratories, Inc., has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Boehringer Ingelheim Pharmaceuticals, Inc.'s Mirapex Tablets (Pramipexole Dihydrochloride) 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg.

20 Feb 2008

People with early Parkinson's more likely to develop hallucinations, sleepiness and swelling

People with early Parkinson's disease report a higher than anticipated development or worsening of hallucinations, sleepiness, and swelling.

10 Jul 2007

Researchers look at whether creatine slows progression of Parkinson's disease

Researchers at the University of Rochester Medical Center are leading one of the largest clinical trials ever for Parkinson's disease.

25 Mar 2007

Therapy for restless legs may trigger compulsive gambling

Compulsive gambling with extreme losses -- in two cases, greater than $100,000 -- by people without a prior history of gambling problems has been linked to a class of drugs commonly used to treat the neurological disorder restless legs syndrome (RLS).

11 Feb 2007

Dopamine drug leads to new neurons and recovery of function in Parkinson's

In preliminary results, researchers have shown that a drug which mimics the effects of the nerve-signaling chemical dopamine causes new neurons to develop in the part of the brain where cells are lost in Parkinson's disease (PD).

5 Jul 2006

Dopamine drug may lead to new ways of treating Parkinson's and other neurodegenerative diseases

Researchers have shown that a drug which mimics the effects of the nerve-signaling chemical dopamine causes new neurons to develop in the part of the brain where cells are lost in Parkinson's disease

4 Jul 2006

First trial of pramipexole for the treatment of fibromyalgia

The mechanism of fibromyalgia, a chronic illness characterized by muscle pain, fatigue, and sleep disturbances, is unknown and medications used to treat it (such as antidepressants, antiepileptics, muscle relaxants, antiinflammatories, sedative hypnotics, pain relievers and nutriceuticals) have had limited success.

28 Jul 2005

Dopamine agonist therapy for Parkinson's disease may lead to problem gambling

Eleven patients with Parkinson's disease (PD) developed pathological gambling behavior following dopamine agonist therapy, a drug therapy to control movement problems caused by Parkinson's disease, according to a study posted online which will appear in the September print issue of Archives of Neurology.

11 Jul 2005

Clinical trial established that two drugs, levodopa and pramipexole, are both viable initial treatments for Parkinson's disease

The four-year clinical trial established that two drugs, levodopa and pramipexole, are both viable initial treatments for Parkinson's disease, a degenerative disorder of the central nervous system.

3 Aug 2004

Clinical study compares treatments in early Parkinson's disease

University of Tennessee Health Science Center professor and vice chair of the Department of Neurology, Ronald F. Pfeiffer, M.D., has been an investigator with The Parkinson Study Group (PSG), which recently reported four-year results of a major long-term, multi-center clinical trial.

21 Jul 2004

Levodopa and pramipexole appear to be reasonable options as initial therapy for Parkinson disease

An article in the July issue of the Archives of Neurology reports that the drugs levodopa and pramipexole both appear to be reasonable options as initial therapy for Parkinson disease, but they are associated with different efficacy and adverse effects.

20 Jul 2004

Study shows MIRAPEX(R) (pramipexole) relieves patients with restless legs syndrome

Results from a large-scale, randomized, double-blind study show MIRAPEX(R) (pramipexole) provides rapid relief in patients with restless legs syndrome (RLS).

28 Apr 2004